BioNxt Solutions Inc. (CVE:BNXT) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 10/10/2025 at 01:55, 1 month 26 days ago

BioNxt Solutions Addresses AGM Voting Amid Postal Strike

AGM Voting Marketing Campaign Canada Post Strike Proxy Submission
PRESS RELEASE

published on 10/10/2025 at 01:50, 1 month 26 days ago

BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities
BioNxt Solutions Inc. provides alternative voting options for shareholders due to Canada Post mail strike. Annual general meeting details and proxy voting instructions shared

Annual General Meeting Shareholders BioNxt Solutions Inc. Proxy Voting Voting Options
BRIEF

published on 10/09/2025 at 09:10, 1 month 26 days ago

BioNxt Completes Fast-Track Patent Filing for MS Treatment

Multiple Sclerosis Cladribine Patent Filing BioNxt Solutions Sublingual Delivery
PRESS RELEASE

published on 10/09/2025 at 09:05, 1 month 26 days ago

BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
BioNxt Solutions Inc. completes Track One priority patent filing with USPTO for sublingual thin-film cladribine formulation (BNT23001) targeting MS & other autoimmune diseases. Strategic move to strengthen IP position & advance regulatory approvals

BioNxt Solutions Inc. Multiple Sclerosis Patent Filing Sublingual Thin-Film Cladribine Formulation
BRIEF

published on 10/02/2025 at 09:10, 2 months 2 days ago

BioNxt Advances Targeted Chemotherapy Drug Delivery Platform

Biopharmaceutical Drug Delivery Research Advancements BioNxt Solutions Targeted Chemotherapy
PRESS RELEASE

published on 10/02/2025 at 09:05, 2 months 2 days ago

BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
BioNxt Solutions Inc. reports significant advancement in targeted chemotherapy delivery platform and upcoming definitive agreement. Proprietary technology aims at 10-fold increase in therapeutic effect while safeguarding healthy cells

BioNxt Solutions Inc. Oncology Treatments Chemotherapy Delivery Platform Targeted Drug Delivery System Therapeutic Effect
BRIEF

published on 09/29/2025 at 09:10, 2 months 5 days ago

BioNxt Advances Cladribine Sublingual Drug Development for Multiple Sclerosis

Drug Development Multiple Sclerosis Cladribine Bioavailability Sublingual
PRESS RELEASE

published on 09/29/2025 at 09:05, 2 months 5 days ago

BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
BioNxt Solutions provides update on Cladribine sublingual thin-film drug reformulation program, targeting treatment of multiple sclerosis with improved bioavailability and patient adherence

Multiple Sclerosis Cladribine Neurological Disorders BioNxt Solutions Drug Delivery Technologies
BRIEF

published on 09/20/2025 at 03:50, 2 months 15 days ago

BioNxt Solutions Completes Shares for Debt Settlement

Common Shares Debt Settlement Debt Agreement Canadian Securities BioNxt Solutions
PRESS RELEASE

published on 09/20/2025 at 03:45, 2 months 15 days ago

BioNxt Solutions Announces Closing of Shares for Debt Settlement
BioNxt Solutions Inc. announces successful debt settlement with creditor, issuing common shares and making cash payment. Company focuses on bioscience innovation and drug delivery technologies

Common Shares Debt Settlement BioNxt Solutions Inc. Drug Delivery Technologies Bioscience Innovation

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 16 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 21 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 51 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 46 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 51 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 3 hours 21 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 26 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 36 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 40 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 51 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 6 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 7 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 50 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE